Cover Image
Market Research Report

Partnerships, Licensing, Investments and M&A Deals and Trends for November 2016 in Pharmaceuticals

Published by GlobalData Product code 248823
Published Content info 92 Pages
Immediate Delivery Available
Price
Back to Top
Partnerships, Licensing, Investments and M&A Deals and Trends for November 2016 in Pharmaceuticals
Published: January 1, 2017 Content info: 92 Pages
Description

GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends for November 2016 in Pharmaceuticals" report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in November 2016. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData's proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.

Scope

  • Analysis of the market trends for the pharmaceutical industry in the global arena.
  • Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
  • Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
  • Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
  • Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
  • Analysis of partnership and licensing deals based on clinical stage of development of products.
  • Summary of the pharmaceutical deals globally in the six months.
  • Information on the top deals happened in the pharmaceutical industry.
  • Geographies covered include - North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
  • League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to buy

  • Enhance your decision making capability in a more rapid and time sensitive manner.
  • Find out the major deal performing segments for investments in your industry.
  • Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
  • Identify companies that are aggressively looking to raise capital in the market
  • Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
  • Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
  • Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
  • Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
  • Identify growth segments and opportunities in each region within the industry.
  • Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.
Table of Contents
Product Code: GDPH0505MD

Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 6
  • 1.2 List of Figures 9

2 Pharmaceuticals & Healthcare, Global, Deal Summary 12

  • 2.1 Pharmaceuticals & Healthcare, Global, Deal Analysis, November 2016 12
  • 2.2 Pharmaceuticals & Healthcare, Global, Major Deals, November 2016 14
    • 2.2.1 Abbott Labs Prices Public Offering of Notes for USD15.1 Billion 14
    • 2.2.2 Pfizer Raises USD6 Billion in Public Offering of Notes 14
    • 2.2.3 Bayer Raises USD4.3 Billion in Private Placement of Convertible Notes due 2019 15
    • 2.2.4 Allergan Acquires Chase Pharma 15
    • 2.2.5 Mitsubishi Tanabe Pharma Enters into Licensing Agreement with Kolon Life Science 16
  • 2.3 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, November 2016 17
  • 2.4 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, November 2016 18

3 Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type 19

  • 3.1 Pharmaceuticals & Healthcare, Global, M&A, November 2016 19
    • 3.1.1 Top M&A Deals in November 2016 20
    • 3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals by Therapy Area, June 2016 - November 2016 21
  • 3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, November 2016 22
    • 3.2.1 Top Equity Offering Deals in November 2016 23
    • 3.2.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, June 2016 - November 2016 24
  • 3.3 Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital Deals, November 2016 25
    • 3.3.1 Top PE/VC Deals in November 2016 26
    • 3.3.2 Pharmaceuticals & Healthcare, Global, PE/VC by Therapy Area, November 2016 27
    • 3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, November 2016 28
    • 3.3.4 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, June 2016-November 2016 29
    • 3.3.5 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, June 2016-November 2016 30
  • 3.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, November 2016 31
  • 3.5 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, June 2016 - November 2016 33
  • 3.6 Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payments and Deal Values (US$ m), November 2016 34
    • 3.6.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals by Payment Mode, November 2016 35
  • 3.7 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), June 2016 - November 2016 36
  • 3.8 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Number Of Deals, June 2016 - November 2016 38
  • 3.9 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Deal Values (US$ m), June 2016 - November 2016 39
  • 3.10 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), June 2016 - November 2016 41

4 Pharmaceuticals & Healthcare, Global, Licensing Agreements, November 2016 43

  • 4.1 Pharmaceuticals & Healthcare, Global, Licensing Agreements, November 2016 43
  • 4.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), November 2016 44
  • 4.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal Values (US$ m), June 2016 - November 2016 45
  • 4.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payments and Milestone Payments (US$ m), June 2016 - November 2016 47
  • 4.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Values (US$ m), June 2016 - November 2016 49
  • 4.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payments and Milestone Payments (US$ m), June 2016 - November 2016 51
    • 4.6.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Deal Value, November 2016 52
    • 4.6.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, November 2016 53
    • 4.6.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Total Milestone Payment, November 2016 53

5 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 54

  • 5.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, November 2016 54
    • 5.1.1 Oncology - Deals of the Month 55
  • 5.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, November 2016 57
    • 5.2.1 Central Nervous System - Deals of the Month 58
  • 5.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, November 2016 60
    • 5.3.1 Infectious Diseases - Deals of the Month 61
  • 5.4 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, November 2016 63
    • 5.4.1 Cardiovascular - Deal of the Month 64
  • 5.5 Pharmaceuticals & Healthcare, Global, Immunology Deals, November 2016 66
    • 5.5.1 Immunology - Deals of the Month 67
  • 5.6 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, November 2016 69
    • 5.6.1 Gastrointestinal - Deal of the Month 70
  • 5.7 Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, November 2016 72
    • 5.7.1 Metabolic Disorders - Deal of the Month 73

6 Deal Summary by Geography 75

  • 6.1 Pharmaceuticals & Healthcare, North America Deals, November 2016 75
    • 6.1.1 North America - Deals of the Month 76
  • 6.2 Pharmaceuticals & Healthcare, Europe, Deals, November 2016 79
    • 6.2.1 Europe - Deals of the Month 80
  • 6.3 Pharmaceuticals & Healthcare, Asia-Pacific, Regional Deals, November 2016 82
    • 6.3.1 Asia-Pacific - Deals of the Month 83
  • 6.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, November 2016 84
    • 6.4.1 Rest of the World - Deals of the Month 85

7 Pharmaceuticals & Healthcare, Global, Top Financial Advisors 86

  • 7.1 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, June 2016 - November 2016 86
  • 7.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, June 2016 - November 2016 87

8 Further Information 89

  • 8.1 Methodology 89
  • 8.2 About GlobalData 90
  • 8.3 Disclosure information 90
  • 8.4 Disclaimer 91

List of Tables

  • Table 1: Pharmaceuticals & Healthcare, Global, Deals Summary, Number of Deals and Deal Values (US$ m), June 2016 - November 2016 13
  • Table 2: Pharmaceuticals & Healthcare, Global, Major Deals, November 2016 14
  • Table 3: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), November 2016 18
  • Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), June 2016 - November 2016 20
  • Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, November 2016 20
  • Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, June 2016 - November 2016 21
  • Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), June 2016 - November 2016 23
  • Table 8: Pharmaceuticals & Healthcare, Global, Top Equity Offering Deals, November 2016 23
  • Table 9: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$ m), June 2016 - November 2016 24
  • Table 10: Pharmaceuticals & Healthcare, Global, PE/VC, Deals Summary, Number of Deals and Deal Values (US$ m), June 2016 - November 2016 26
  • Table 11: Pharmaceuticals & Healthcare, Global, Top PE/VC Deals, November 2016 26
  • Table 12: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Deals Summary, June 2016 - November 2016 27
  • Table 13: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals and Deal Values (%), November 2016 29
  • Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), June 2016 - November 2016 30
  • Table 15: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, June 2016 - November 2016 30
  • Table 16: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), June 2016 - November 2016 32
  • Table 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), June 2016 - November 2016 33
  • Table 18: Pharmaceuticals & Healthcare, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), June 2016 - November 2016 34
  • Table 19: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront and Milestone Payments and Deal Values (US$ m), November 2016 35
  • Table 20: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), June 2016 - November 2016 37
  • Table 21: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, June 2016 - November 2016 40
  • Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payment and Deal values (US$ m), June 2016 - November 2016 42
  • Table 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), June 2016 - November 2016 43
  • Table 24: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront and Milestone Payments and Deal Values (US$ m), June 2016 - November 2016 44
  • Table 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), June 2016 - November 2016 45
  • Table 26: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments (US$ m), November 2016 48
  • Table 27: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, June 2016 - November 2016 50
  • Table 28: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), November 2016 52
  • Table 29: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Value, November 2016 52
  • Table 30: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Upfront Payments, November 2016 53
  • Table 31: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Milestone Payment, November 2016 53
  • Table 32: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), June 2016 - November 2016 55
  • Table 33: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), June 2016 - November 2016 58
  • Table 34: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Deals Summary, Number of Deals and Deal Values (US$ m), June 2016 - November 2016 61
  • Table 35: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), June 2016 - November 2016 64
  • Table 36: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), June 2016 - November 2016 67
  • Table 37: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), June 2016 - November 2016 70
  • Table 38: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), June 2016 - November 2016 73
  • Table 39: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), June 2016 - November 2016 76
  • Table 40: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), June 2016 - November 2016 80
  • Table 41: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), June 2016 - November 2016 83
  • Table 42: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), June 2016 - November 2016 85
  • Table 43: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), June 2016 - November 2016 86
  • Table 44: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), June 2016 - November 2016 87

List of Figures

  • Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$ m), June 2016 - November 2016 12
  • Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), November 2016 17
  • Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), November 2016 18
  • Figure 4: Pharmaceuticals & Healthcare, Global, M&As, Number of Deals and Deal Values (US$ m), June 2016 - November 2016 19
  • Figure 5: Pharmaceuticals & Healthcare, Global, M&As by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, June 2016 - November 2016 21
  • Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), June 2016 - November 2016 22
  • Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, Number of Deals and Deal Values (US$ m), June 2016 - November 2016 24
  • Figure 8: Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital, Number of Deals and Deal Values (US$ m), June 2016 - November 2016 25
  • Figure 9: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, June 2016 - November 2016 27
  • Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals (%), November 2016 28
  • Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Deal Values (%), November 2016 28
  • Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), June 2016 - November 2016 29
  • Figure 13: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), June 2016 - November 2016 31
  • Figure 14: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), June 2016 - November 2016 33
  • Figure 15: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), June 2016 - November 2016 34
  • Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), June 2016 - November 2016 36
  • Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, June 2016 - November 2016 38
  • Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, June 2016 - November 2016 39
  • Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), June 2016 - November 2016 41
  • Figure 20: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), June 2016 - November 2016 43
  • Figure 21: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), June 2016 - November 2016 44
  • Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), June 2016 - November 2016 45
  • Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), June 2016 - November 2016 47
  • Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Number Of Deals, June 2016 - November 2016 49
  • Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Deal Values (US$ m), June 2016 - November 2016 50
  • Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), November 2016 51
  • Figure 27: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), June 2016 - November 2016 54
  • Figure 28: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), June 2016 - November 2016 57
  • Figure 29: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Number of Deals and Deal Values (US$ m), June 2016 - November 2016 60
  • Figure 30: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), June 2016 - November 2016 63
  • Figure 31: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), June 2016 - November 2016 66
  • Figure 32: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), June 2016 - November 2016 69
  • Figure 33: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), June 2016 - November 2016 72
  • Figure 34: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), June 2016 - November 2016 75
  • Figure 35: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), June 2016 - November 2016 79
  • Figure 36: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), June 2016 - November 2016 82
  • Figure 37: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), June 2016 - November 2016 84
  • Figure 38: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), June 2016 - November 2016 86
  • Figure 39: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), June 2016 - November 2016 87
Back to Top